Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer

NCT06549465 is registered in ClinicalTrials.gov with Convergent Therapeutics as lead sponsor.

NCT NCT06549465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06549465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer
Lead sponsor
Convergent Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
August 6, 2024
Completion date
October 31, 2031
Enrollment
93 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

psma pet-positive castration-resistant prostate cancer